Freenome vs Proscia Concentriq
Proscia's Concentriq has a clinical lab line for case review and a life sciences line for biomarker research, trials and companion diagnostics, so its customers are diagnostic laboratories and biopharma. Concentriq AP-Dx holds two 510(k)s, K230839 from February 8, 2024 and K261380 from August 5, 2026, and press coverage says the second adds the Leica Aperio GT 450 DX, cloud deployment and a PCCP. SOC 2 Type II was announced on December 3, 2025. Agilent announced on October 13, 2026 a deal to buy Proscia for up to $270 million, pending as of October 15, 2026 with closing expected early in Agilent's fiscal 2027.
Freenome's SimpleScreen CRC is for a clinician screening adults 45 and older at average risk. In the vendor's prespecified, census-adjusted analysis it showed 81.1% sensitivity for colorectal cancer, 13.7% for advanced precancerous lesions and 90.4% specificity for advanced neoplasia.
Pathology · Reviewed November 2, 2026
Freenome
by Freenome · founded 2014
FDA-approved SimpleScreen CRC blood test for colorectal cancer screening in adults 45 and older at average risk.
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
When to pick each one
Freenome
- Vendor-reported 81.1% sensitivity for colorectal cancer
- Vendor-reported 90.4% specificity for advanced neoplasia
Proscia Concentriq
- Two 510(k)s, latest K261380 in August 2026
- SOC 2 Type II announced December 2025
- Case review and AI apps in one platform
Score
Each row shows points earned of points available under the published rubric.
Freenome
40of 100
Proscia Concentriq
40of 100
| Dimension | Freenome | Proscia Concentriq | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 6 / 10 | -6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 0 / 21 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Freenome
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Proscia Concentriq
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request only. |
Evidence
Freenome
FDA decisions
P250029 (opens in new tab)PMA2026-07-24
SimpleScreen CRC
Proscia Concentriq
FDA decisions
K261380 (opens in new tab)510(k)2026-08-05
Concentriq AP-Dx
K230839 (opens in new tab)510(k)2024-02-08
Concentriq Dx (marketed as Concentriq AP-Dx)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Freenome | Proscia Concentriq |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2014 | n/a |
| HQ | US | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.